Compare BridgeBio Pharma Inc (BBIO) vs Morgan Stanley (MS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Morgan Stanley — how do they compare? BridgeBio Pharma Inc trades at $82.82 (market cap $16.46B), while Morgan Stanley trades at $228.8 (market cap $359.10B). The key difference: Morgan Stanley is far larger — about 21.8× BridgeBio Pharma Inc's market cap, and Morgan Stanley pays a 1.76% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | MS | |
|---|---|---|
Market Cap | $16.46B | $359.10B |
Sector | Health | Financials |
52-Week High | $90.17 | $228.17 |
52-Week Low | $44.81 | $139.09 |
Enterprise Value | $18.02B | — |
Dividend Yield | — | 1.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
Morgan Stanley (MS) trades at $221.09, down 0.54% on the day, with a bullish technical signal from moving averages and strong fundamental performance including three consecutive quarterly earnings beats. Revenue grew to $66.0B in 2025 with net income margin expanding to 25.56%, while analyst consensus remains positive with a $225.80 price target. Recent news highlights the firm's role in leading Anthropic's upcoming IPO and expanding AI integration in wealth management.
The outlook for MS is favorable given earnings momentum and strategic positioning in high-growth areas like AI and IPO advisory, though risks include volatile cash flows and high debt levels. The stock presents a potential 2.1% upside to the consensus target, supported by 53.85% analyst buy ratings, but investors should monitor interest expense and macroeconomic impacts on financial services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →
